Published in Hepatitis Weekly, September 1st, 2003
According to recent research from the Peoples Republic of China, "artificial liver support system (ALSS) has been used to treat hepatic failure and has significantly decreased mortality. TECA hybrid artificial liver support system (TECA-HALSS), which combines the hollow fiber bioreactor with a plasma exchange circuit, was used to assess the efficacy, safety and feasibility in treating severe hepatitis patients."
"The hybrid artificial liver support system (HALSS) consists of a bioreactor containing more than 5 x 109 porcine hepatocytes and plasma exchange device," explained...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.